Zentalis shares surge 12.35% intraday as company announces participation in Guggenheim Biotech Summit investor conference.

Zentalis Pharmaceuticals (ZNTL) surged 12.35% intraday following the announcement that its management team will participate in a fireside discussion at Guggenheim's Biotech Summit 2026 on February 11. The event, featuring live and archived webcast access, highlights the company’s progress in developing azenosertib, a first-in-class WEE1 inhibitor for ovarian cancer. This visibility likely boosted investor confidence, aligning with recent analyst ratings such as a "Moderate Buy" from brokerages and a "Strong-Buy" from HC Wainwright. While some news items, like a Wells Fargo price target cut to $5, introduced mixed signals, the investor conference participation and positive analyst sentiment were the primary drivers of the intraday rally.